<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ying L</submitter><funding>Public Health Agency of Canada</funding><funding>Tanoto Foundation</funding><funding>U.S. Department of Defense</funding><funding>National Health and Medical Research Council</funding><funding>National Medical Research Council</funding><pagination>402-414</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10952994</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>259(4)</volume><pubmed_abstract>Mucosa-associated lymphoid tissue (MALT) lymphoma is a B-cell tumour that develops over many decades in the stomachs of individuals with chronic Helicobacter pylori infection. We developed a new mouse model of human gastric MALT lymphoma in which mice with a myeloid-specific deletion of the innate immune molecule, Nlrc5, develop precursor B-cell lesions to MALT lymphoma at only 3 months post-Helicobacter infection versus 9-24 months in existing models. The gastric B-cell lesions in the Nlrc5 knockout mice had the histopathological features of the human disease, notably lymphoepithelial-like lesions, centrocyte-like cells, and were infiltrated by dendritic cells (DCs), macrophages, and T-cells (CD4&lt;sup>+&lt;/sup> , CD8&lt;sup>+&lt;/sup> and Foxp3&lt;sup>+&lt;/sup> ). Mouse and human gastric tissues contai</pubmed_abstract><journal>The Journal of pathology</journal><pubmed_title>Anti-CD40L therapy prevents the formation of precursor lesions to gastric B-cell MALT lymphoma in a mouse model.</pubmed_title><pmcid>PMC10952994</pmcid><funding_grant_id>APP2012620</funding_grant_id><funding_grant_id>W81XWH‐17‐1‐0606</funding_grant_id><funding_grant_id>APP1079904</funding_grant_id><funding_grant_id>NMRC‐OFLCG‐18May0028</funding_grant_id><funding_grant_id>APP1107930</funding_grant_id><pubmed_authors>Tran LS</pubmed_authors><pubmed_authors>Yu L</pubmed_authors><pubmed_authors>Xu P</pubmed_authors><pubmed_authors>Ferrero RL</pubmed_authors><pubmed_authors>Liu P</pubmed_authors><pubmed_authors>Ong CK</pubmed_authors><pubmed_authors>Ying L</pubmed_authors><pubmed_authors>Cheah DM</pubmed_authors><pubmed_authors>Philpott DJ</pubmed_authors><pubmed_authors>Lim ST</pubmed_authors><pubmed_authors>Ding Z</pubmed_authors><pubmed_authors>Colon N</pubmed_authors><pubmed_authors>Emery J</pubmed_authors><pubmed_authors>Tu Y</pubmed_authors><pubmed_authors>Cheng CL</pubmed_authors><pubmed_authors>Wray-McCann G</pubmed_authors><pubmed_authors>Le LH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Anti-CD40L therapy prevents the formation of precursor lesions to gastric B-cell MALT lymphoma in a mouse model.</name><description>Mucosa-associated lymphoid tissue (MALT) lymphoma is a B-cell tumour that develops over many decades in the stomachs of individuals with chronic Helicobacter pylori infection. We developed a new mouse model of human gastric MALT lymphoma in which mice with a myeloid-specific deletion of the innate immune molecule, Nlrc5, develop precursor B-cell lesions to MALT lymphoma at only 3 months post-Helicobacter infection versus 9-24 months in existing models. The gastric B-cell lesions in the Nlrc5 knockout mice had the histopathological features of the human disease, notably lymphoepithelial-like lesions, centrocyte-like cells, and were infiltrated by dendritic cells (DCs), macrophages, and T-cells (CD4&lt;sup>+&lt;/sup> , CD8&lt;sup>+&lt;/sup> and Foxp3&lt;sup>+&lt;/sup> ). Mouse and human gastric tissues contai</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-22T13:02:42.03Z</modification><creation>2024-11-15T04:02:29.696Z</creation></dates><accession>S-EPMC10952994</accession><cross_references><pubmed>36640261</pubmed><doi>10.1002/path.6053</doi></cross_references></HashMap>